BCL9 and C9orf5 Are Associated with Negative Symptoms in Schizophrenia: Meta-Analysis of Two Genome-Wide Association Studies

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Xu, Chun ^a   Aragam, Nagesh ^b,c   Li, Xia ^d   Villla, Erika Cynthia ^e   Wang, Liang ^b   Briones, David ^a   Petty, Leonora ^a   Posada, Yolanda ^f   Arana, Tania Bedard ^a   Cruz, Grace ^a   Mao, ChunXiang ^g   Camarillo, Cynthia ^a   Su, Brenda Bin ^g   Escamilla, Michael A ^a   Wang, KeSheng ^b  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS AT EL PASO   (United States)

^f WALDEN UNIVERSITY   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BCL9 GENE; BINDING AFFINITY; BINDING SITE; C9ORF5 GENE; CONTROLLED STUDY; CTNNA3 GENE; DISEASE ACTIVITY; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NEGATIVE SYNDROME; NF385D GENE; QUALITY CONTROL; RNA BINDING; RNF144 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; ST3GAL1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 84873879420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051674     Document Type: Article

References (54)

1. Sullivan PF, Kendler KS, Neale MC, (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of general psychiatry 60: 1187-1192.
2. Gejman PV, Sanders AR, Duan J, (2010) The role of genetics in the etiology of schizophrenia. The Psychiatric clinics of North America 33: 35-66.
3. Kendler KS, Neale MC, (2010) Endophenotype: a conceptual analysis. Molecular psychiatry 15: 789-797.
4. Cannon TD, Keller MC, (2006) Endophenotypes in the genetic analyses of mental disorders. Annual review of clinical psychology 2: 267-290.
5. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, et al. (2011) Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry 168: 930-946.
6. Lecrubier Y, (2008) Refinement of diagnosis and disease classification in psychiatry. European archives of psychiatry and clinical neuroscience 258Suppl 1: 6-11.
7. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR, (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia bulletin 32: 214-219.
8. Montgomery SA, van Zwieten-Boot B, (2007) ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 17: 70-77.
9. Itokawa M, Arinami T, Toru M, (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. Journal of pharmacological sciences 114: 1-5.
10. Bishop JR, Ellingrod VL, Moline J, Miller D, (2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophrenia research 77: 253-260.
11. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, et al. (2004) Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 7: 461-470.
12. Simpson EH, Kellendonk C, Ward RD, Richards V, Lipatova O, et al. (2011) Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biological psychiatry 69: 928-935.
13. Addington J, Addington D, Maticka-Tyndale E, (1991) Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophrenia research 5: 123-134.
14. Berman I, Viegner B, Merson A, Allan E, Pappas D, et al. (1997) Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia research 25: 1-10.
15. Potkin SG, Macciardi F, Guffanti G, Fallon JH, Wang Q, et al. (2010) Identifying gene regulatory networks in schizophrenia. NeuroImage 53: 839-847.
16. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
17. Nieratschker V, Nothen MM, Rietschel M, (2010) New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia? Frontiers in behavioral neuroscience 4: 23.
18. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, et al. (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature genetics 40: 1053-1055.
19. Sanders AR, Duan J, Levinson DF, Shi J, He D, et al. (2008) No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. The American journal of psychiatry 165: 497-506.
20. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, et al. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460: 753-757.
21. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer research 68: 6162-6170.
22. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, et al. (2011) Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular psychiatry 16: 321-332.
23. Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, et al. (2009) Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. American journal of human genetics 85: 13-24.
24. Bassett AS, Scherer SW, Brzustowicz LM, (2010) Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. The American journal of psychiatry 167: 899-914.
25. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, et al. (1998) Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91: 1873-1881.
26. de la Roche M, Worm J, Bienz M, (2008) The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC cancer 8: 199.
27. Gould TD, Gray NA, Manji HK, (2003) Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacological research: the official journal of the Italian Pharmacological Society 48: 49-53.
28. Li J, Zhou G, Ji W, Feng G, Zhao Q, et al. (2011) Common variants in the BCL9 gene conferring risk of schizophrenia. Archives of general psychiatry 68: 232-240.
29. Zandi PP, Belmonte PL, Willour VL, Goes FS, Badner JA, et al. (2008) Association study of Wnt signaling pathway genes in bipolar disorder. Archives of general psychiatry 65: 785-793.
30. International Schizophrenia Consortium, (2008) Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
31. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, et al. (2008) Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
32. Duan J, Sanders AR, Gejman PV, (2010) Genome-wide approaches to schizophrenia. Brain research bulletin 83: 93-102.
33. Malhotra D, Sebat J, (2012) CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. Cell 148: 1223-1241.
34. Blumenfeld A, Slaugenhaupt SA, Axelrod FB, Lucente DE, Maayan C, et al. (1993) Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. Nature genetics 4: 160-164.
35. Chadwick BP, Gill S, Leyne M, Mull J, Liebert CB, et al. (1999) Cloning, genomic organization and expression of a putative human transmembrane protein related to the Caenorhabditis elegans M01F1.4 gene. Gene 240: 67-73.
36. Luciano M, Hansell NK, Lahti J, Davies G, Medland SE, et al. (2011) Whole genome association scan for genetic polymorphisms influencing information processing speed. Biological psychology 86: 193-202.
37. Zhang P, Xiang N, Chen Y, Sliwerska E, McInnis MG, et al. (2010) Family-based association analysis to finemap bipolar linkage peak on chromosome 8q24 using 2,500 genotyped SNPs and 15,000 imputed SNPs. Bipolar disorders 12: 786-792.
38. Zandi PP, Zollner S, Avramopoulos D, Willour VL, Chen Y, et al. (2008) Family-based SNP association study on 8q24 in bipolar disorder. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 612-618.
39. Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, et al. (2008) Family-based association study of lithium-related and other candidate genes in bipolar disorder. Archives of general psychiatry 65: 53-61.
40. Ono K, Tomasiewicz H, Magnuson T, Rutishauser U, (1994) N-CAM mutation inhibits tangential neuronal migration and is phenocopied by enzymatic removal of polysialic acid. Neuron 13: 595-609.
41. Arai M, Yamada K, Toyota T, Obata N, Haga S, et al. (2006) Association between polymorphisms in the promoter region of the sialyltransferase 8B (SIAT8B) gene and schizophrenia. Biological psychiatry 59: 652-659.
42. Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA, (2009) Evidence for disruption of sphingolipid metabolism in schizophrenia. Journal of neuroscience research 87: 278-288.
43. Davis OS, Butcher LM, Docherty SJ, Meaburn EL, Curtis CJ, et al. (2010) A three-stage genome-wide association study of general cognitive ability: hunting the small effects. Behavior genetics 40: 759-767.
44. Miyashita A, Arai H, Asada T, Imagawa M, Matsubara E, et al. (2007) Genetic association of CTNNA3 with late-onset Alzheimer's disease in females. Human molecular genetics 16: 2854-2869.
45. Morgan AR, Hamilton G, Turic D, Jehu L, Harold D, et al. (2008) Association analysis of 528 intra-genic SNPs in a region of chromosome 10 linked to late onset Alzheimer's disease. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 727-731.
46. Smith JD, Meehan MH, Crean J, McCann A, (2011) Alpha T-catenin (CTNNA3): a gene in the hand is worth two in the nest. Cellular and molecular life sciences: CMLS 68: 2493-2498.
47. Ciani L, Salinas PC, (2005) WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nature reviews Neuroscience 6: 351-362.
48. Meencke HJ, Veith G, (1999) The relevance of slight migrational disturbances (microdysgenesis) to the etiology of the epilepsies. Advances in neurology 79: 123-131.
49. Volk DW, Lewis DA, (2010) Prefrontal cortical circuits in schizophrenia. Current topics in behavioral neurosciences 4: 485-508.
50. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nature genetics 40: 1056-1058.
51. Weidle UH, Eggle D, Klostermann S, Swart GW, (2010) ALCAM/CD166: cancer-related issues. Cancer genomics & proteomics 7: 231-243.
52. Velligan DI, Alphs LD (2008) Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment. Psychiatric Time 25.
53. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81: 559-575.
54. Purcell S, Cherny SS, Sham PC, (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150.